Caris Life Sciences Inc's stock surged 20.43% in pre-market trading on Friday, following the release of its quarterly earnings report that significantly exceeded analyst expectations.

The medical equipment company reported adjusted earnings of 8 cents per share for the quarter ended September 30, beating the mean analyst expectation of a loss of 21 cents per share. The company also reported quarterly net income of $81.96 million. While revenue of $216.83 million came in slightly below the $239.03 million analysts had expected, the substantial earnings beat appears to be driving investor optimism.

Analyst sentiment toward the company had been improving prior to the report, with the mean earnings estimate rising approximately 115% over the last three months. The current average analyst rating on the shares remains "buy," with a median 12-month price target of $37.50. Separately, JP Morgan adjusted its price target for Caris Life Sciences to $35 from $40, though this revision appears to have been overshadowed by the positive earnings results.